Kepler Capital Keeps Their Buy Rating on Hyloris Pharmaceuticals SA (52U)
Kepler Capital analyst Christophe dombu maintained a Buy rating on Hyloris Pharmaceuticals SA (52U – Research Report) on June 17 and set a price target of €16.00. The company's shares closed last Monday at €5.68.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, dombu is an analyst with an average return of -6.8% and a 37.50% success rate. dombu covers the Healthcare sector, focusing on stocks such as Hyloris Pharmaceuticals SA, MaaT Pharma, and Onward Medical N.V..
Currently, the analyst consensus on Hyloris Pharmaceuticals SA is a Moderate Buy with an average price target of €16.00.
Based on Hyloris Pharmaceuticals SA's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €2.7 million and a GAAP net loss of €1.43 million. In comparison, last year the company earned a revenue of €1.53 million and had a GAAP net loss of €4.37 million
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Microsoft's Exit from Talks Threatens OpenAI's For-Profit Transition
Tech giant Microsoft (MSFT) is considering withdrawing from heated negotiations with artificial intelligence (AI) startup OpenAI. The two are engaged in high-stakes talks regarding the size of Microsoft's future stake in the ChatGPT maker, should it turn into a public-benefit entity. CEO Sam Altman believes that a for-profit corporation would enable the company to raise funds more easily and even pursue an IPO (Initial Public Listing) in the future. Confident Investing Starts Here: Notably, OpenAI needs to transform into a for-profit structure to access the funds from its most recent funding round, or investors could walk away. In the worst-case scenario, some may convert their equity funding into debt. For instance, one of its largest backers, Japan's SoftBank (SFTBY), might reduce its funding by $10 billion, from the initially planned $30 billion. Microsoft must approve the conversion by the end of this year. Multibillion-Dollar Partnership at Risk Microsoft has invested over $13 billion in OpenAI since its initial funding in 2019. The companies are negotiating the size of MSFT's equity stake, which could range from 20% to 49% in the restructured entity. However, the two seem to have reached an impasse regarding their future relationship. A Financial Times report stated that if the parties fail to reach an agreement, Microsoft could withdraw and continue to rely on its existing contract, which grants it access to OpenAI's technology until 2030. Notably, the tech giant has exclusive rights to sell access to OpenAI's AI models and tools through Azure Cloud and receives a 20% share of OpenAI's revenues. Microsoft is unwilling to give up either benefit, as this exclusivity gives it an edge over rivals Alphabet (GOOGL) and Meta Platforms (META) in the AI race. Meanwhile, this fallout has led OpenAI to consider legal action, threatening to take Microsoft to court and accusing it of anticompetitive behavior. Moreover, OpenAI is complaining that Microsoft is unable to deliver the enhanced computing power required to run and train its advanced ChatGPT models. The AI firm boasts 500 million weekly active users worldwide. Their partnership has indeed been a productive one, delivering advanced AI tools to the masses and widely regarded as one of the most important in the technology sector. Both parties are said to be in daily discussions on the subject, and their recent joint statement reads, 'Talks are ongoing and we are optimistic we will continue to build together for years to come.' Furthermore, once this hurdle is cleared, OpenAI must receive approval from attorneys general in Delaware and California to convert to a for-profit structure. Additionally, OpenAI must contend with billionaire Elon Musk 's lawsuit, which seeks to halt the transformation. Is Microsoft a Good Stock to Buy? Analysts remain highly optimistic about Microsoft's long-term stock trajectory. On TipRanks, MSFT stock has a Strong Buy consensus rating based on 31 Buys and five Hold ratings. The average Microsoft price target of $518.77 implies 8% upside potential from current levels. Year-to-date, MSFT stock has gained 14.4%.
Business Insider
an hour ago
- Business Insider
DR Horton (DHI) Receives a Buy from Evercore ISI
Evercore ISI analyst Stephen Kim maintained a Buy rating on DR Horton (DHI – Research Report) yesterday and set a price target of $167.00. The company's shares closed yesterday at $121.28. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Kim covers the Consumer Cyclical sector, focusing on stocks such as Lennar, Installed Building Products, and DR Horton. According to TipRanks, Kim has an average return of 14.1% and a 57.49% success rate on recommended stocks. In addition to Evercore ISI, DR Horton also received a Buy from Wells Fargo's Deepa Raghavan in a report issued on June 11. However, on June 16, Texas Capital Securities initiated coverage with a Hold rating on DR Horton (NYSE: DHI).
Business Insider
an hour ago
- Business Insider
DBS Reaffirms Their Buy Rating on MINISO Group Holding Ltd. (9896)
In a report released today, Clement Xu from DBS maintained a Buy rating on MINISO Group Holding Ltd. (9896 – Research Report). The company's shares opened today at HK$35.55. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Xu is a 3-star analyst with an average return of 3.3% and a 58.18% success rate. Xu covers the Consumer Defensive sector, focusing on stocks such as Budweiser Brewing Co. APAC Ltd., China Mengniu Dairy Co, and China Resources Beer (Holdings) Co. The word on The Street in general, suggests a Strong Buy analyst consensus rating for MINISO Group Holding Ltd. with a HK$43.40 average price target. The company has a one-year high of HK$55.00 and a one-year low of HK$20.00. Currently, MINISO Group Holding Ltd. has an average volume of 10.31M.
